Morgan Bayer

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

Neoadjuvant enfortumab vedotin displayed promising outcomes for cisplatin-ineligible MIBC patients, achieving a 2-year EFS rate of 62.0%. Safety was affirmed with no treatment-related delays in surgery.

The inavolisib regimen, designed for PIK3CA-mutated breast cancer, and NVL-655 for ALK-positive NSCLC, have received FDA breakthrough designations, and infigratinib has lost FDA approval for cholangiocarcinoma. We also discuss targeted therapies reshaping NSCLC treatment, and the safety and efficacy of TNO155 combinations across various solid tumors.

Interim results show promising efficacy of palazestrant/ribociclib in ER+/HER2– metastatic breast cancer, an approval for tarlatamab-dlle, and data suggesting early ctDNA kinetics as a potential pharmacodynamic biomarker. We also cover the initiation of dosing quaratusugene ozeplasmid/atezolizumab in SCLC and more.

A correlation between non–small cell lung cancer and influenza shows a decrease in cancer survival rates.

Experts explore challenges in brain tumor management, and nivolumab/ipilimumab fails to improve PFS in NSCLC. We also cover access to 177Lutetium-PSMA-617, developments in mRNA cancer vaccine WGc-043, and antibody-drug conjugate 9MW2821 in esophageal cancer.

According to a recent analysis, preliminary circulating tumor DNA kinetics could serve as an early pharmacodynamic biomarker, offering potential for early biologic proof of concept.

A BLA for subcutaneous nivolumab in solid tumors, lenvatinib becoming primary treatment in thyroid cancer, and expert discussions on IO/TKI combos in RCC. We also cover positive results from acalabrutinib combination in MCL and pembrolizumab combination in HER2-positive gastric cancer.

T-DXd enhances survival in HR+/HER2-low breast cancer, and immunotherapy combo is recommended for advanced SCLC. We also highlight recent FDA approvals and challenges associated with legislative changes.

EG-70, a novel, nonviral gene therapy, elicited a 73% complete response at any time for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.

Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.

Recent FDA approvals such as tovorafenib, nogapendekin, and alectinib, are included in this recap. We also cover boxed warnings for CAR T-cell therapies and analysis advancements for papillary thyroid microcarcinoma.

In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.

In this weekly recap ODAC endorses MRD for accelerated myeloma trial approval, research delves into ovarian cancer trends in Asian American populations, amivantamab’s variable efficacy in NSCLC, and more.

The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.

Emerging NK-cell therapies offer faster, safer alternatives to CAR T-cell therapy, improving accessibility and reducing manufacturing challenges. T-DXd shows promise in treating HER2+ tumors, and HPV vaccine offerings during abortion care visits improve vaccination rates.

Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.

This week's Targeted Pulse focuses on the latest in cervical cancer, the FDA ODAC's vote for cilta-cel, and more.

This week's Targeted Pulse focuses on the latest in the treatment landscapes of small cell lung cancer, myeloma, and more.

From bispecific antibodies transforming B-cell lymphoma treatment to immunotherapy breakthroughs in breast cancer and gene therapy innovations for hematologic malignancies, recent advancements offer hope.

Orca-T therapy boosts survival in elderly with hematologic cancer, while trilaciclib shows promise in triple-negative breast cancer treatment.

New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.

Allina Health Cancer Institute and Astrin Biosciences are jointly integrating AI to improve the assessment of cancer cells in blood samples, beginning with breast cancer, which faces challenges with mammogram imaging and demands innovative solutions.

A bounty of FDA drug approvals have arrived plus the pivotal role of cytoreductive therapy and more.

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.

The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.

This week's Targeted Pulse touches on the latest in cancer news and research updates.

This edition of Targeted Pulse dives into the exciting realm of cutting-edge cancer therapies on the horizon.